000153.CS▲
Fengyuan Pharmaceutical's wholly-owned subsidiary obtains drug registration certificate for vonoprazan fumarate tablets
Anhui Fengyuan Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for vonoprazan fumarate tablets issued by the National Medical Products Administration. The approved strengths are 10 mg and 20 mg, both classified as Category 4 chemical drugs, and the drug approval number is valid until August 24, 2031. Vonoprazan fumarate is a potassium-competitive acid blocker used to treat reflux esophagitis and Helicobacter pylori infection. The company stated that this approval will enrich its product line, optimize its product structure, and enhance market competitiveness, but drug production and sales are subject to industry policies and market conditions, and uncertainties remain.
Local state capital plans to take control of Fengyuan Pharmaceutical; shares hit limit up
Fengyuan Pharmaceutical opened at the daily limit up on August 18, trading at 6.68 yuan per share, with a total market value of about 3.104 billion yuan. On the previous trading day evening, the company disclosed that three concert parties of its controlling shareholder Fengyuan Group signed a share transfer agreement with Bengbu Investment Group, under which the Bengbu municipal state-owned capital platform plans to acquire a 21.53% stake in the company. The proposed transfer involves a total of 100,037,121 shares at a price of 6.41 yuan per share, a premium of about 7.9% over the August 14 closing price of 5.94 yuan, with a total transaction value of about 641 million yuan. If the deal is completed, the listed company's controlling shareholder will change to Bengbu Investment Group, and its actual controller will change to the Bengbu Municipal State-owned Assets Supervision and Administration Commission. The transferee has committed not to transfer the underlying shares to outside parties within 60 months after the share transfer registration is completed, not to pledge the shares within 36 months, and not to inject its own or related parties' assets into the listed company within 36 months.
000153.CS▼
Li Rongjie to lose control of Fengyuan Pharmaceutical, Fengyuan Group no longer holds any A-share listed company
Fengyuan Pharmaceutical announced that three concert parties under its controlling shareholder Fengyuan Group plan to transfer their equity to Bengbu Investment Group. After the transaction, the controlling shareholder will change to Bengbu Investment Group, the actual controller will change from Li Rongjie to the Bengbu Municipal State-owned Assets Supervision and Administration Commission, and Fengyuan Group and its concert parties will no longer hold any shares in Fengyuan Pharmaceutical. Li Rongjie took over Bengbu Citric Acid Plant in 1994 and built the Fengyuan Group, which once owned three A-share listed companies: Fengyuan Biochemical, Fengyuan Pharmaceutical, and ST Taifu. However, Fengyuan Biochemical changed hands to COFCO Group in 2006, and control of ST Taifu fell to Shandong state-owned capital in 2012. With this transfer of control over Fengyuan Pharmaceutical, the Fengyuan Group will no longer have any actual controlling stake in an A-share listed company. Zhang Jun, board secretary of Fengyuan Pharmaceutical, said the matter is still in the planning stage and information is limited to the announcement. As of June 16, 2026, Fengyuan Group's total outstanding borrowings of various types amounted to approximately 11.5 billion yuan, with about 1.5 billion yuan due for repayment in the coming year, while net profit in the first quarter of 2026 was only 134 million yuan, indicating significant debt pressure.
Fengyuan Pharmaceutical's actual controller to change to Bengbu SASAC
Fengyuan Pharmaceutical announced that a concert party of its controlling shareholder, Anhui Fengyuan Group, has signed a share transfer intention agreement with Bengbu Investment Group. Bengbu Investment Group plans to acquire 109 million shares, representing 23.52% of the company's total share capital. After the transaction, Bengbu Investment Group will become the new controlling shareholder, and the company's actual controller will change from Li Rongjie to the Bengbu State-owned Assets Supervision and Administration Commission.
000153.CS▲
Zhejiang Meida Plans Control Change, Trading Halted from July 10
Zhejiang Meida announced that controlling shareholder and actual controller Xia Zhisheng and Xia Ding are planning a major matter that may lead to a change in company control. Trading in the company's shares will be halted from July 10, expected to last no more than two trading days. The counterparty is in the cross-border e-commerce industry, with a share transfer ratio within 30 percent and no prior approval from authorities required. Previously, Zhejiang Meida's share price hit three daily limit-up moves in five trading days. On the same day, Fengyuan Pharmaceutical announced that Bengbu Investment Group plans to acquire 109 million shares of the company through a negotiated transfer, representing 23.52 percent of total share capital. The transaction is based on a total market value of 2.98 billion yuan, corresponding to an amount of approximately 700 million yuan. Upon completion, the controlling shareholder will change to Bengbu Investment Group, and the actual controller will change to the Bengbu Municipal State-owned Assets Supervision and Administration Commission.
China